LifeStance Health Group, Inc. (NASDAQ:LFST) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $8.32.

Separately, JPMorgan Chase & Co. increased their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, August 10th.

LifeStance Health Group Trading Up 2.0 %

Shares of LifeStance Health Group stock opened at $7.01 on Friday. The firm has a market capitalization of $2.65 billion, a PE ratio of -15.24 and a beta of 0.99. LifeStance Health Group has a 1 year low of $4.22 and a 1 year high of $9.59. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average is $8.28 and its 200 day moving average is $7.97.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, August 9th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). LifeStance Health Group had a negative return on equity of 10.86% and a negative net margin of 17.13%. The business had revenue of $259.60 million for the quarter, compared to the consensus estimate of $255.19 million. During the same period in the previous year, the firm earned ($0.19) earnings per share. The company’s revenue was up 23.9% compared to the same quarter last year. Equities research analysts forecast that LifeStance Health Group will post -0.27 earnings per share for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other news, insider Kevin Michael Mullins sold 65,832 shares of the firm’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $9.02, for a total transaction of $593,804.64. Following the completion of the sale, the insider now directly owns 5,370,616 shares of the company’s stock, valued at approximately $48,442,956.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Warren Gouk sold 11,966 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $8.25, for a total value of $98,719.50. Following the sale, the insider now directly owns 5,856,262 shares in the company, valued at approximately $48,314,161.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Michael Mullins sold 65,832 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $9.02, for a total transaction of $593,804.64. Following the sale, the insider now directly owns 5,370,616 shares in the company, valued at approximately $48,442,956.32. The disclosure for this sale can be found here. Insiders sold 413,195 shares of company stock worth $3,659,456 in the last quarter. 8.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC bought a new position in shares of LifeStance Health Group in the first quarter worth $136,000. JPMorgan Chase & Co. increased its stake in LifeStance Health Group by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 283,852 shares of the company’s stock valued at $2,870,000 after acquiring an additional 8,624 shares during the last quarter. Bank of New York Mellon Corp increased its stake in LifeStance Health Group by 43.4% in the first quarter. Bank of New York Mellon Corp now owns 227,173 shares of the company’s stock valued at $2,297,000 after acquiring an additional 68,759 shares during the last quarter. MetLife Investment Management LLC increased its stake in LifeStance Health Group by 138.7% in the first quarter. MetLife Investment Management LLC now owns 42,066 shares of the company’s stock valued at $425,000 after acquiring an additional 24,446 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in LifeStance Health Group by 50.0% in the first quarter. Rhumbline Advisers now owns 72,743 shares of the company’s stock valued at $735,000 after acquiring an additional 24,252 shares during the last quarter. 76.98% of the stock is currently owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.